Table 1.
Change in body weight during the treatment.
| Treatment Group (n = 6 Per Group) |
Body Weight (gram) | Day 1 | Day 4 | Day 8 | Day 11 | Day 14 |
|---|---|---|---|---|---|---|
| Non-treated control | Mean ± SD | 22.0 ± 0.9 | 22.8 ± 0.8 | 24.0 ± 0.6 | 24.2 ± 0.8 | 24.3 ± 1.0 |
| Anamorelin | Mean ± SD | 22.2 ± 0.8 | 23.4 ± 0.5 | 24.2 ± 0.8 | 24.4 ± 0.5 | 24.2 ± 0.8 |
| p value (vs control) | n.s. | n.s. | n.s. | n.s. | n.s. | |
| 5-ALA | Mean ± SD | 22.6 ± 0.5 | 23.4 ± 0.5 | 23.8 ± 1.6 | 24.0 ± 0.7 | 23.6 ± 0.5 |
| p value (vs control) | n.s. | n.s. | n.s. | n.s. | n.s. | |
| GC alone | Mean ± SD | 22.2 ± 0.8 | 21.6 ± 1.3 | 20.2 ± 1.3 | 20.0 ± 1.6 | 22.4 ± 1.1 |
| p value (vs control) | n.s. | n.s. | 0.004 | 0.004 | 0.028 | |
| GC plus anamorelin | Mean ± SD | 22.2 ± 0.8 | 22.8 ± 1.1 | 22.1 ± 1.2 | 22.2 ± 2.2 | 23.9 ± 1.1 |
| p value (vs GC alone) | n.s. | n.s. | 0.032 | 0.071 | 0.055 | |
| GC plus 5-ALA | Mean ± SD | 22.2 ± 0.8 | 22.0 ± 1.0 | 20.4 ± 1.5 | 19.2 ± 1.3 | 21.8 ± 0.8 |
| p value (vs GC alone) | n.s. | n.s. | n.s. | n.s. | n.s. | |
| p value (multiple comparison for six treatment groups) | n.s. | n.s. | 0.0014 | 0.0039 | 0.011 |
SD = standard deviation; 5-ALA = 5-aminolevulinic acid; GC = combined chemotherapy of gemicitabine and cisplatin; n.s. = not significant; p values are based on the comparison of the values at each treatment time point relative to the non-treated control group or GC alone group with using multiple comparison (the Kruskal-Wallis test) and the post hoc test (Dunn test).